Current body fluid diagnostic biomarkers for AD used in the clinic include the determination of levels of CSF Aβ42, which reflects the presence of parenchymal senile plaque aggregates, in combination with increased levels of total tau (tTau) and phosphorylated tau (pTau) that reflect NFT [15–17]. This evidence concerns the gene MAPT and Alzheimer disease.